Your browser doesn't support javascript.
loading
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Hong, David S; Van Tine, Brian A; Biswas, Swethajit; McAlpine, Cheryl; Johnson, Melissa L; Olszanski, Anthony J; Clarke, Jeffrey M; Araujo, Dejka; Blumenschein, George R; Kebriaei, Partow; Lin, Quan; Tipping, Alex J; Sanderson, Joseph P; Wang, Ruoxi; Trivedi, Trupti; Annareddy, Thejo; Bai, Jane; Rafail, Stavros; Sun, Amy; Fernandes, Lilliam; Navenot, Jean-Marc; Bushman, Frederic D; Everett, John K; Karadeniz, Derin; Broad, Robyn; Isabelle, Martin; Naidoo, Revashnee; Bath, Natalie; Betts, Gareth; Wolchinsky, Zohar; Batrakou, Dzmitry G; Van Winkle, Erin; Elefant, Erica; Ghobadi, Armin; Cashen, Amanda; Grand'Maison, Anne; McCarthy, Philip; Fracasso, Paula M; Norry, Elliot; Williams, Dennis; Druta, Mihaela; Liebner, David A; Odunsi, Kunle; Butler, Marcus O.
Afiliação
  • Hong DS; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dshong@mdanderson.org.
  • Van Tine BA; Section of Medical Oncology, Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
  • Biswas S; Adaptimmune, Abingdon, Oxfordshire, UK.
  • McAlpine C; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Johnson ML; Sarah Cannon Cancer Institute, Tennessee Oncology/One Oncology, Nashville, TN, USA.
  • Olszanski AJ; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Clarke JM; Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Araujo D; Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Blumenschein GR; Department of Thoracic-Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin Q; Adaptimmue, Philadelphia, PA, USA.
  • Tipping AJ; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Sanderson JP; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Wang R; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Trivedi T; Adaptimmue, Philadelphia, PA, USA.
  • Annareddy T; Adaptimmue, Philadelphia, PA, USA.
  • Bai J; Adaptimmue, Philadelphia, PA, USA.
  • Rafail S; Adaptimmue, Philadelphia, PA, USA.
  • Sun A; Adaptimmue, Philadelphia, PA, USA.
  • Fernandes L; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Navenot JM; Adaptimmue, Philadelphia, PA, USA.
  • Bushman FD; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.
  • Everett JK; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.
  • Karadeniz D; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA.
  • Broad R; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Isabelle M; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Naidoo R; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Bath N; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Betts G; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Wolchinsky Z; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Batrakou DG; Adaptimmune, Abingdon, Oxfordshire, UK.
  • Van Winkle E; Adaptimmue, Philadelphia, PA, USA.
  • Elefant E; Adaptimmue, Philadelphia, PA, USA.
  • Ghobadi A; Section of Medical Oncology, Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
  • Cashen A; Section of Medical Oncology, Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
  • Grand'Maison A; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • McCarthy P; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Fracasso PM; Adaptimmue, Philadelphia, PA, USA.
  • Norry E; Adaptimmue, Philadelphia, PA, USA.
  • Williams D; Adaptimmue, Philadelphia, PA, USA.
  • Druta M; Sarcoma Medical Oncology, Moffitt Cancer Center, Tampa, FL, USA.
  • Liebner DA; Department of Internal Medicine, Division of Medical Oncology, and Department of Biomedical Informatics, Division of Computational Biology and Bioinformatics, Ohio State University, Columbus, OH, USA.
  • Odunsi K; University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL, USA.
  • Butler MO; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Nat Med ; 29(1): 104-114, 2023 01.
Article em En | MEDLINE | ID: mdl-36624315
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in multiple solid tumors. We conducted a multicenter, dose-escalation, phase 1 trial in patients with relapsed/refractory metastatic solid tumors expressing MAGE-A4, including synovial sarcoma (SS), ovarian cancer and head and neck cancer ( NCT03132922 ). The primary endpoint was safety, and the secondary efficacy endpoints included overall response rate (ORR) and duration of response. All patients (N = 38, nine tumor types) experienced Grade ≥3 hematologic toxicities; 55% of patients (90% Grade ≤2) experienced cytokine release syndrome. ORR (all partial response) was 24% (9/38), 7/16 (44%) for SS and 2/22 (9%) for all other cancers. Median duration of response was 25.6 weeks (95% confidence interval (CI): 12.286, not reached) and 28.1 weeks (95% CI: 12.286, not reached) overall and for SS, respectively. Exploratory analyses showed that afami-cel infiltrates tumors, has an interferon-γ-driven mechanism of action and triggers adaptive immune responses. In addition, afami-cel has an acceptable benefit-risk profile, with early and durable responses, especially in patients with metastatic SS. Although the small trial size limits conclusions that can be drawn, the results warrant further testing in larger studies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço / Antígenos de Neoplasias Tipo de estudo: Clinical_trials Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço / Antígenos de Neoplasias Tipo de estudo: Clinical_trials Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article